

BOSENTAN TREATMENT FOR AUTOIMMUNE DISEASES

CP-141

Monforte Gasque MP¹, Lacalle Fabo E¹, Castresana Elizondo M¹, Fanlo Mateo P², Gutierrez Valencia M¹, Carrasco del Amo ME¹, Elviro Llorens M¹, Pellejero Hernando E¹, Monteserin Garrastatxu I¹

¹ Complejo Hospitalario de Navarra, Pharmacy Service, Pamplona, Spain

² Complejo Hospitalario de Navarra, Internal Medicine Service, Pamplona, Spain

OBJECTIVES

The objective is the evaluation of the effectiveness and safety of Bosentan in the treatment of clinical manifestations associated with underlying autoimmune disease in each patient:

- Raynaud's phenomenon (RP)
- Digital ulcers (DU) and other location skin ulcers (SU)

STUDY DESIGN

- Retrospective observational (January 2012-September 2014).
- Compassionate use was applied in all cases before treatment starting.


PATIENTS	Sex, age, underlying disease, indication, previous treatments, dose, follow-up time
EFFECTIVENESS	Absence new of ulcers, improvement of the basal ulcers and decrease in the number of Raynaud's phenomenon episodes
SAFETY	Adverse reactions

RESULTS


PATIENTS

- ✓ 14 patients
- 10 female
- ✓ Median age 52 years (25-81)
- ✓ Follow-up 22 months (2-55)
- ✓ All of them had been previously treated with first-line treatment


11 patients: to treat RP and prevention/recovery DU



3 patients: to treat other location SU



EFFECTIVENESS



SAFETY

2 cases: the treatment was discontinued due to digestive intolerance

2 cases: the dose was adjusted as a consequence of an initial raise of the hepatic parameters

CONCLUSIONS

- Bosentan may be considered an appropriate alternative in these diseases which had been refractory to the conventional therapies.
- The number of patients is limited due to the low prevalence of these diseases and to the off-label use of the drug.
- The research's value lies on the possibility of opening new therapeutic perspectives with this drug.

ACKNOWLEDGEMENTS

I want to thank Esther Lacalle Fabo, Marta Castresana Elizondo, Beatriz Sánchez Castellanos and Patricia Fanlo Mateo for their support and time.